Literature DB >> 8166364

Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia.

L G Mitchell1, J M Halton, P A Vegh, R D Barr, T Venneri, K M Pai, M E Andrew.   

Abstract

PURPOSE: We sought to determine the effect of disease and combination chemotherapy on the hemostatic system in children with acute lymphoid leukemia (ALL). PATIENTS AND METHODS: We conducted a prospective study of children newly diagnosed with ALL. Plasma samples were obtained at four time points: at diagnosis before therapy, 5 days after administration of L-asparaginase alone, after the remission induction program, and at completion of the consolidation phase. Plasma levels of 21 hemostatic proteins were measured. The amount of thrombin generated following activation with an APTT reagent was quantitated.
RESULTS: At diagnosis there were significant elevations in factors VIII, IX, von Willebrand, alpha 2-macroglobulin and protein S. In contrast, there were significant reductions in protein C, prekallikrein, and factors XIIIA and XIIIS. L-asparaginase treatment alone decreased concentrations of 11 proteins, with antithrombin III being affected to the greatest extent. After multiagent chemotherapy, not including L-asparaginase, concentrations of most proteins increased to or above baseline. At completion of consolidation therapy, which included weekly L-asparaginase administration, concentrations of most proteins were decreased compared with baseline values. The amount of thrombin generated following activation with an APTT reagent was similar to adults.
CONCLUSION: Plasma concentrations of coagulation proteins are affected by disease (ALL) alone and by combination chemotherapy with or without L-asparaginase. There is no impairment of in vitro capacity to generate thrombin. L-asparaginase alone caused a decrease in almost all proteins; however, ATIII was affected to the greatest extent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166364

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  8 in total

Review 1.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

2.  Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.

Authors:  Lesley Mitchell; Moritz Lambers; Silke Flege; Gili Kenet; Valerie Li-Thiao-Te; Susanne Holzhauer; Christoph Bidlingmaier; Michael C Frühwald; Christine Heller; Wolfgang Schmidt; Brigitte Pautard; Ulrike Nowak-Göttl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

3.  Coagulation Profile at Diagnosis in Patients with Acute Lymphoblastic Leukemia.

Authors:  Shivali Sehgal; Sunita Sharma; Jagdish Chandra; Anita Nangia
Journal:  Indian J Pediatr       Date:  2016-04-25       Impact factor: 1.967

Review 4.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

5.  Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>.

Authors:  Jason N Barreto; Kristen B McCullough; Candy S Peskey; Ross A Dierkhising; Kristin C Mara; Michelle A Elliott; Dennis A Gastineau; Aref Al-Kali; Naseema Gangat; Louis Letendre; William J Hogan; Mark R Litzow; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2017-05-09

6.  The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

Authors:  Rachael F Grace; Suzanne E Dahlberg; Donna Neuberg; Stephen E Sallan; Jean M Connors; Ellis J Neufeld; Daniel J Deangelo; Lewis B Silverman
Journal:  Br J Haematol       Date:  2011-01-07       Impact factor: 6.998

Review 7.  Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis?

Authors:  Vilmarie Rodriguez
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

Review 8.  Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.

Authors:  Nobuko Hijiya; Inge M van der Sluis
Journal:  Leuk Lymphoma       Date:  2015-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.